Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Respiratory Distress Syndrome, Adult D012128 15 associated lipids
Epilepsy D004827 35 associated lipids
Seizures D012640 87 associated lipids
Nerve Degeneration D009410 53 associated lipids
Birth Weight D001724 23 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Nasal Polyps D009298 26 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Ear Diseases D004427 7 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Respiratory Hypersensitivity D012130 18 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Agranulocytosis D000380 7 associated lipids
Shock D012769 11 associated lipids
Polycythemia Vera D011087 13 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Fever D005334 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Pneumococcal Infections D011008 7 associated lipids
Thrombocytopenia D013921 15 associated lipids
Bronchial Spasm D001986 18 associated lipids
Shock, Septic D012772 11 associated lipids
Immune Complex Diseases D007105 9 associated lipids
Conjunctivitis D003231 7 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Death, Sudden D003645 12 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Cardiomegaly D006332 31 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Carbon Monoxide Poisoning D002249 9 associated lipids
Neutropenia D009503 15 associated lipids
Extravasation of Diagnostic and Therapeutic Materials D005119 3 associated lipids
Meningioma D008579 11 associated lipids
Multiple Trauma D009104 2 associated lipids
Cluster Headache D003027 4 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Glomerulonephritis, IGA D005922 7 associated lipids
Behcet Syndrome D001528 7 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Migraine Disorders D008881 11 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Ou MC et al. Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure. 1994 Thromb. Res. pmid:8191415
Le Blanc K et al. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. 1998 Thromb. Res. pmid:9772010
Eche N et al. Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). 1986 Thromb. Res. pmid:3726808
Slattery CW and Beaumont DO Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors. 1989 Thromb. Res. pmid:2554526
Nguyên P et al. Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. 1995 Thromb. Res. pmid:7778064
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Namm DH and High JA Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. 1980 Thromb. Res. pmid:7209881
Hanss M and Dechavanne M 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. 1988 Thromb. Res. pmid:3126559
Okamoto M et al. Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. 1986 Thromb. Res. pmid:3754990
Sturk A et al. Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. 1985 Thromb. Res. pmid:2934863
Shukla SD et al. Hypersensitivity of diabetic human platelets to platelet activating factor. 1992 Thromb. Res. pmid:1329254
Westwick J et al. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. 1986 Thromb. Res. pmid:3715810
Valone FH Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. 1987 Thromb. Res. pmid:3590086
Tokumura A et al. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. 1987 Thromb. Res. pmid:3590110
Ishii H et al. Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. 1990 Thromb. Res. pmid:2382255
Wade PJ et al. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. 1986 Thromb. Res. pmid:3961730
Hofmann B et al. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. 1988 Thromb. Res. pmid:3381200
Cox CP and Wood KL Selective antagonism of platelet-activating factor (PAF)-induced aggregation and secretion in washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. 1987 Thromb. Res. pmid:3629553
Catalán RE et al. Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. 1994 Thromb. Res. pmid:7974386
Ostermann G et al. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. 1987 Thromb. Res. pmid:3629555
Heinrich J and Zimmermann RE Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. 1984 Thromb. Res. pmid:6523451
Hwang SB et al. Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. 1984 Thromb. Res. pmid:6429890
Petty AC and Scrutton MC Platelet aggregation in whole blood: is the response to adrenaline, 5-hydroxytryptamine and PAF a direct consequence of stimulation by these agonists? 1989 Thromb. Res. pmid:2749609
Janero DR et al. Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. 1988 Thromb. Res. pmid:3413730
Moon DG et al. Platelet activating factor and sheep platelets: a sensitive new bioassay. 1990 Thromb. Res. pmid:2326773
Violi F et al. Human platelet aggregation by PAF and thromboxane production. 1987 Thromb. Res. pmid:3424290
Klöcking HP et al. Release of tissue-type plasminogen activator by platelet-activating factor. 1985 Thromb. Res. pmid:4040278
Cox CP Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. 1986 Thromb. Res. pmid:2421432
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Croft KD and Beilin LJ Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. 1993 Thromb. Res. pmid:8385810
Vrzheshch PV et al. Cell response kinetics: the phenomenon of supercooperativity in aggregation of human platelets. 1992 Thromb. Res. pmid:1523610
Teng CM et al. Antiplatelet actions of some coumarin compounds isolated from plant sources. 1992 Thromb. Res. pmid:1523611
Kohayakawa M and Inoue K Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. 1986 Thromb. Res. pmid:3083530
Tencé M et al. Ether-phospholipid composition in neutrophils and platelets. 1985 Thromb. Res. pmid:4024039
Hadváry P and Baumgartner HR Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. 1983 Thromb. Res. pmid:6868019
Leoncini G et al. Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. 1997 Thromb. Res. pmid:9175236
Tan EL and Snyder F Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by capillary endothelial cells isolated from rat epididymal adipose tissue. 1985 Thromb. Res. pmid:4024051
Despotis GJ et al. Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. 1997 Thromb. Res. pmid:9175242
Ding YA et al. Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. 1995 Thromb. Res. pmid:7740521
Bussolino F et al. Intravascular release of platelet activating factor in children with sepsis. 1987 Thromb. Res. pmid:3441909
Küster LJ and Frölich JC PAF-induced platelet aggregation and TXB2 formation. 1989 Thromb. Res. pmid:2922704
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Pfliegler G et al. Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. 1993 Thromb. Res. pmid:8503122
Altman R et al. Why single daily dose of aspirin may not prevent platelet aggregation. 1988 Thromb. Res. pmid:3140408
Lukaszyk A et al. Does acute experimental pancreatitis affect blood platelet function? 1989 Thromb. Res. pmid:2524119
Lecompte T et al. Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. 1990 Thromb. Res. pmid:2117306
McGowan EB and Detwiler TC Characterization of the thrombin-induced desensitization of platelet activation by thrombin. 1983 Thromb. Res. pmid:6356458
Mabilat-Pragnon C et al. Urokinase localization and activity in isolated eosinophils. 1997 Thromb. Res. pmid:9526961
May JA et al. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. 1997 Thromb. Res. pmid:9361371
Lian EC et al. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. 1984 Thromb. Res. pmid:6420930